Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

F-star Therapeutics logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

Advanced Chart

Key Stats

Today's Range
$7.12
$7.12
50-Day Range
$4.42
$7.12
52-Week Range
$2.07
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FSTX Stock News Headlines

Astria Therapeutics price target raised to $28 from $26 at Oppenheimer
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Bicara Therapeutics Rises 39% in Debut on Nasdaq
See More Headlines

FSTX Stock Analysis - Frequently Asked Questions

F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.06. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $7.18 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

Last Earnings
11/10/2021
Today
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,280,000.00
Pretax Margin
-213.97%

Debt

Sales & Book Value

Annual Sales
$21.17 million
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
1.51

Miscellaneous

Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:FSTX) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners